Find and Pitch Jounalists, Get Your Story Covered

Tags: leadership pharma Research & Development research-development biotech

	Profile	Recent Articles on Subject
1	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	What 3 layoff stories reveal about pharma’s troubles - 10 days ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 3 months ago Where competition is heating up in pharma - 4 months ago 3 big recent trial flops - 5 months ago The biggest questions hanging over pharma in 2024 - 8 months ago Pharma execs sound off on trends and policies they’re tracking in 2024 - 8 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 8 months ago 10 of our most read articles in 2023 - 9 months ago Does BioMarin’s CEO shuffle signal bigger changes ahead? - 10 months ago PharmaVoice 100s: Entrepreneurs - 11 months ago PharmaVoice 100s: Clinical trial gurus - 11 months ago
2	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	BioMarin’s big day today - 12 days ago STAT+: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu - 4 months ago
3	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Is pharma still fearful of the Inflation Reduction Act? - about 1 month ago The biotech news you missed this week - 2 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 4 months ago The Senate health committee looks into its first subpoena in 40 years - 8 months ago The biotech updates you need to read today - 9 months ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - 9 months ago FDA chastens pet companies over antibiotics - 9 months ago The biotech news you missed from the weekend - 9 months ago Novartis is building a new radioligand plant in China - 10 months ago Johnson & Johnson bets heavy on AI-driven drug discovery - 10 months ago Today’s biotech news roundup, in under 800 words - 10 months ago A new algorithm unveils CRISPR ‘treasure trove’ - 10 months ago These are the need-to-know biotech stories from this weekend - 10 months ago XBI biotech index rises, giving investors a shred of hope - 11 months ago Your Monday morning biotech news roundup - 11 months ago Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO - 11 months ago Candor on gene therapy, Abiomed is warned, & BTK success in MS - 11 months ago
4	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - about 1 month ago Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 4 months ago 4 offbeat biotechs making a splash in the life sciences - 5 months ago How a biotech exec is leveraging Big Pharma lessons to advance tRNA - 5 months ago
5	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	A biotech’s binary bet ends badly - 3 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 4 months ago
6	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	Listen: More tumult at BIO & coercive care for sickle cell patients - 4 months ago
7	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	June 2024 - 4 months ago 2024 - 8 months ago
8	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - 5 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 6 months ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - 10 months ago
9	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	When did Wall Street sour on Lilly’s Alzheimer’s drug? - 6 months ago Another step toward new drugs for Parkinson’s - 8 months ago The XBI comedown after JPM - 8 months ago BioMarin appeases an activist - 9 months ago Is it time to worry about Moderna? - 9 months ago A plot to solve the ‘whack-a-mole’ of drug discovery - 9 months ago Tome Biosciences goes public today in another biotech megaround - 9 months ago Eli Lilly’s latest $1.4 billion deal might come unglued - 9 months ago Legend Biotech’s deal with Novartis is a reminder that biotech’s bear market has a few haves, and many have-nots - 10 months ago Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis - 11 months ago Why AstraZeneca’s CEO is accusing British tabloids of ‘fake news’ - 11 months ago What if there’s no market for a CRISPR cure? - 11 months ago Cell and gene therapies could be a safer bet than other drugs - 11 months ago With Ozempic, Wall Street moves on from a whole other class of medicines - 11 months ago
10	Alexandra Pecci Pharma Voice Leading community for life sciences leaders. Washington, D.C. pharmaceuticalslife sciencescommunity building	Ferring’s microbiome and gene therapy firsts take the company beyond reproductive health - 7 months ago 4 biotechs to watch in 2024 - 7 months ago 5 noteworthy pharma AI investments in 2023 - 9 months ago The fortunes and flops of pharma M&A - 10 months ago Biopharma’s top 5 IPOs of 2023 (so far) - 10 months ago The power of genomics-based healthcare remains largely untapped - 10 months ago In a record year for biotech bankruptcy, here are 3 companies that went under - 11 months ago To close the pediatric innovation gap, this biotech has to think differently - 11 months ago

Journalists covering biopharma journalism